Reductive effect of ursodeoxycholic acid on bilirubin levels in neonates on phototherapy.
Maduka Donatus Ughasoro, Gilbert Nwadiaka Adimorah, Ndubuisi Kennedy Chukwudi...
https://pubmed.ncbi.nlm.nih.gov/31534356/Actively Recruiting
Led by Tishreen University Hospital · Updated on 2026-04-21
70
Participants Needed
1
Research Sites
6 weeks
Total Duration
Researchers are investigating the effect of Ursodeoxycholic Acid UDCA combined with triple phototherapy in treating indirect hyperbilirubinemia in newborns born at or after 34 weeks of gestation. This open-label, randomized controlled trial aims to see if adding UDCA can help lower bilirubin levels faster or reduce the time needed for phototherapy compared to phototherapy alone. The study is conducted at Lattakia University Hospital and includes stratification based on jaundice cause, such as hemolytic, non-hemolytic, or G6PD deficiency. Newborns meeting the criteria will be randomly assigned to one of two groups one receiving continuous triple phototherapy alone, and the other receiving the same phototherapy plus oral UDCA at 10 mg per kg per day split into two doses. The UDCA is given with feeding until bilirubin levels fall below the treatment threshold. Phototherapy follows American Academy of Pediatrics guidelines, and participants are monitored closely during treatment. Parents can expect their newborns to have bilirubin levels checked every 12 hours until discharge. The main measures are the time and rate at which bilirubin decreases below phototherapy thresholds within seven days. Secondary outcomes include hospital stay length, bilirubin reduction differences between late preterm and term infants, need for retreatment, and monitoring for any side effects in the UDCA group. The study continues until bilirubin normalizes or treatment ends, with follow-up up to 10 days after discontinuation.
CONDITIONS
The Efficacy of Ursodeoxycholic Acid (UDCA) as Adjuvant Therapy to Phototherapy in the Management of Neonatal Indirect Hyperbilirubinemia
A
Ashraf M Alshelly, MD, Ped.Res.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tishreen University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment
Duration - Up to 7 days
Participants receive continuous triple phototherapy, with some also receiving oral ursodeoxycholic acid (UDCA) as add-on therapy until bilirubin levels decrease below the phototherapy threshold.
Bilirubin levels monitored every 12 hours during treatment
Duration - Up to 3 days
Participants are monitored for up to 3 days after treatment discontinuation to assess the need for retreatment and any adverse effects.
1 to 2 visits after treatment ends
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Maduka Donatus Ughasoro, Gilbert Nwadiaka Adimorah, Ndubuisi Kennedy Chukwudi...
https://pubmed.ncbi.nlm.nih.gov/31534356/C M Rodrigues, C J Steer
https://pubmed.ncbi.nlm.nih.gov/11772248/Mehrdad Rezaie, Roya Gholami, Mahtab Jafari...
https://pubmed.ncbi.nlm.nih.gov/33682983/Tishreen University Hospital
Lead Sponsor